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Abstract 
Takotsubo syndrome is an acute cardiac syndrome first described in 1990 and 
characterized by transient left ventricular dysfunction affecting more than one 
coronary artery territory, and often in a circumferential apical, mid-ventricular or basal 
distribution. A number of pathophysiological explanations for this syndrome with its 
intriguing appearance have been proposed, and there is a growing awareness that 
these are not mutually exclusive, and that the reversible apical myocardial 
dysfunction observed could result from more than one pathophysiological 
phenomenon. The pathophysiology of takotsubo syndrome is complex, with 
integration of both neuroendocrine physiology involving the cognitive centres of the 
brain and hypothalamic-pituitary-adrenal axis, and the cardiovascular responses to 
the sudden sympathetic activation and surge in circulating catecholamines. The latter 
have been explored in detail, starting with the histological findings at biopsy, with the 
multiple morphological changes seen in the myocardium matching those seen after 
established catecholamine cardiotoxic effects. Clinically, both the acute prognosis 
and recurrence rate are unfortunately worse than previously reported. It is clear that 
the modern cardiology community has much still to learn regarding the epidemiology 
and the underlying pathophysiology of this fascinating condition in order to improve 
diagnostic and treatment pathways.  
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Key points 
 Approximately 2% of all patients presenting to the hospitals with suspected acute 
coronary syndrome are usually identified with takotsubo syndrome. There is a 
predominance in post-menopausal women compared to men or younger women. 
 Both the acute and long-term mortality are higher than previously recognized. 
The cumulative incidence of recurrence increased from 1.2% at first 6 months to 
nearly 5% at 6 years, and there is no current evidence to support treatment with 
any specific to prevent recurrence. 
 Systemic surges in catecholamines may cause vascular effects including acute 
coronary vasospasm and severe acute hypertension due to acute peripheral 
vasospasm followed by later peripheral vasodilation and hypotension. In the 
clinical setting, profound hypotension and cardiogenic shock is a common 
complication, however, it is not solely related to the extent of impairment of left 
ventricular (LV) systolic function, and thus probably relates in part to 
inappropriate peripheral vasodilation. 
 Biopsies during acute takotsubo syndrome are characterized by multiple 
morphological changes that are similar to those after catecholamine cardiotoxic 
effects supporting a direct effect in addition to the vascular influences. 
 The apical myocardium of the left ventricle has the highest density of β-
adrenergic receptors (βAR), and is therefore most sensitive to circulating 
catecholamines. 
 High epinephrine levels result in a switch from the Gs stimulatory to the 
cardioinhibitory Gi secondary messenger pathway within the cardiomyocyte, 
which β2AR-Gi pathway activation is cardioprotective. However, this theory may 
not account for atypical anatomical variants of takotsubo syndrome. 
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Introduction 
In recent decades a novel cardiac syndrome with transient left ventricular dysfunction 
has been reported all over the world. This new entity has been referred to as 
“takotsubo cardiomyopathy” or “takotsubo syndrome”, after the octopus fishing pot in 
Japanese, due to the particular shape and appearance of the left ventricle at end-
systole observed with left ventriculography or echocardiography during the acute 
phase1. This syndrome has been classified as a primary and acquired 
cardiomyopathy according to the American Heart Association Scientific Statement2 
and also classified as an unclassified cardiomyopathies according to the European 
Society of Cardiology Position Statement3 ; however whether it is a true 
cardiomyopathy remains to be determined - it can be considered clinically as an 
acute cardiac syndrome with reversible heart failure. This syndrome has been called 
various names in the medical literature including “takotsubo cardiomyopathy”, “stress 
cardiomyopathy”, “apical ballooning”, and “broken heart syndrome” when triggered 
following bereavement. A mini epidemic occurred after the earthquakes in 
Christchurch, New Zealand in 2010 and in 20114. US data have also shown small 
epidemics during the devastation caused by Hurricane Irene and during the worst 
tornado to hit the United States in 2011. This article primarily addresses the 
epidemiology and the currently discussed pathophysiological concepts of this novel 
cardiac syndrome.  
 
Epidemiology 
Diagnosis: Diagnostic criteria have been previously proposed from a few centres 
around the world (Table 1), and several diagnostic references have been proposed5-9. 
However, a worldwide consensus has not been fully established, but it is clear 
following the initial reports from Japan that this syndrome is observed throughout the 
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world, and is not unique to Japanese population. The largest reported cohort data 
comes from the Nationwide Inpatient Sample (NIS) from the United States, based 
upon ICD-9 discharge coding.10 In 2008 the NIS analyzed 6,837 patients with 
takotsubo syndrome. It confirmed the previously recurrent trend from smaller cohorts 
that the condition most frequently affects postmenopausal women. Approximately 
90% of the takotsubo syndrome patients in the NIS cohort were aged 50 years or 
more, 90% patients were female, and 70% patients were in the white ethnic group. 
Only 1% Asian patients were included in this large cohort, perhaps reflecting the 
demographic of patients in the hospitals providing data to the NIS.  
Across many different series, approximately 2% of all patients presenting to the 
hospitals with suspected acute coronary syndrome are usually identified with 
takotsubo syndrome 6, 11, 12, with the postmenopausal female predominance 
described above 13-16. If only female cases with suspected acute coronary syndrome 
are considered, up to 10% patients are ultimately diagnosed with takotsubo 
syndrome 10. The initial NIS study demonstrated that approximately 0.02% of all 
hospitalizations (6,837 patients out of the 33,560,402 patients with all diseases) were 
diagnosed as having takotsubo syndrome 10, and subsequent reports from the same 
group suggest the incidence is approximately 100 new cases per million population 
per annum. 
The evolution of diagnostic criteria reflect a change from a diagnosis of exclusion 
(apical bulge/no coronary disease) to a recognition that takotsubo syndrome has a 
number of characteristic features. For example is a condition of catecholamine-
stimulated myocardial stunning and on acute imaging may have evidence of 
inflammation. The detection of myocardial oedema in affected segments on 
cardiovascular magnetic resonance using T2STIR sequences helps to clarify this 
pathophysiology. The increasing recognition that takotsubo syndrome and bystander 
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coronary disease may coexist also is important to remember, as not all patients with 
takotsubo syndrome have normal coronary arteries. 
 
Emotional and/or physical stress frequently, but not always, precedes this syndrome. 
A range of typical stressors is listed in Table 2. They often reflect common stresses 
encountered in daily life, and it is perhaps not unsurprising that we encounter this 
syndrome so frequently now that it is recognised. A variety of non-cardiac acute 
diseases may also trigger takotsubo syndrome (see Table 2).  
 
Takotsubo syndrome can be challenging to differentiate from acute coronary 
syndrome because many of its symptoms, clinical signs, echocardiographic and 
electrocardiographic findings are superficially similar to those in patients with acute 
coronary syndrome e.g. cardiac chest pain, ST elevation, regional wall motion 
abnormalities. Takotsubo syndrome is usually diagnosed by using coronary 
angiography depicting the absence of culprit coronary stenoses to explain the 
regional wall motion abnormalities which extend beyond a single coronary artery 
territory. Access to urgent invasive diagnostic coronary angiography is mandatory for 
patients presenting with acute chest pain and ST elevation. However if presentation 
is delayed (e.g. >48 hours, or pain free and stable at presentation), then CT coronary 
angiography may have a role as an alternative imaging investigation to exclude 
coronary stenosis in stable patients suspected of takotsubo syndrome 17.  
Electrocardiographic (ECG) abnormalities are usually present in patients with 
takotsubo syndrome 18-26, i.e. ST-segment elevation acutely, and subsequently deep 
and widespread T-wave inversion; these changes evolve and depend on the time 
from the stress and symptom onset to clinical presentation and ECG recording. While 
 7 
several studies suggest criteria which can differentiate takotsubo syndrome from 
acute myocardial infarction, no clear criteria have been found to be highly sensitive 
and specific. The presence of ST elevation makes it challenging to distinguish from 
ST-elevated myocardial infarction, and access to emergency coronary angiography 
should not be delayed21-26. Kosuge et al. reported the differences in the distribution of 
ST-segment elevation between takotsubo syndrome and STEMI 22. Most patients 
with anterior acute myocardial infarction have ST-segment elevation in leads V2 to 
V4. On the contrary, in patients with takotsubo syndrome, ST-segment elevation 
most frequently occurs in leads II, III, aVF, aVR and V5-6 facing the apical and 
inferolateral regions. The wall motion abnormalities in takotsubo syndrome less 
frequently extend to the V1-lead regions. Accordingly, typical takotsubo syndrome is 
distinguished from acute anterior myocardial infarction with the 90% or more 
sensitivity and specificity22. Various anatomical variants of takotsubo syndrome have 
been reported, including the classical apical variant, the midventricular variant and 
the basal or inverted variant11,15,16,27,28 To date there is no evidence for the 
usefulness of ECG in distinguishing the anatomical variants with diagnostic accuracy. 
The incidence of atypical anatomical variants (non-apical) in takotsubo syndrome is 
ranged from 8.4% to 40%11,15,28; the prevalence of mid-ventricular type is at least 
20%, and that of basal type is about 3%, so these are also not rare given the overall 
number of cases occurring. 
In this syndrome, there is predominance in post-menopausal women than men or 
younger women previously described. Estrogen is thought to contrbute to the 
mechanism of this syndrome onset according to the results from the animal 
experiment29. Chronic estrogen supplimentation could partially attenuate the excess 
of cardiovascular response against stress30. However, no clinical trial regarding the 
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estrogen replacement therapy for prevention in patients with takotsubo syndrome has 
been appeared. In case of men, this estrogen theory does not fit to explain, hence 
further studies are required to clarify the reason why post-menopausal women tend 
to occur. 
Prognosis 
Mortality: The prognosis of takotsubo syndrome was initially reported in a relatively 
favorable manner in comparison to STEMI31; however, subsequent studies have 
demonstrated that both the acute10 and long-term32, 33 mortality are higher than 
previously recognized. Pre-hospital mortality is unknown and this should not be 
underestimated; the mortality during the acute phase in hospitalized patients is ~4-
5%, and comparable with modern STEMI. Furthermore despite the recovery of LV 
function and absence of stenotic coronary artery disease, the mortality after hospital 
discharge is also remarkably poor and worse than an aged-matched healthy 
population. Intriguingly the prognosis is greatly influenced by non-cardiac diseases 34, 
reflecting the many cases of secondary takotsubo syndrome, where the triggering 
medical condition may impart the poor prognosis14. Citro et al. reported that 
approximately 50% of cases of takotsubo syndrome in their Italian takotsubo registry 
aged 75 years or more had complications35. They also noted the complication rate 
was higher in patients ≥75 years than those <75 years, and they revealed the higher 
in-hospital complication rate. This has been recently reinforced by similar findings 
from the German takotsubo registry36. In the largest published cohorts, the in-hospital 
mortality is 2.2% in Germany and Austria37, 2.6% in Italy38, 4.2% in the U.S.A.39, 
6.8% in Japan16, and 4.5% in the results obtained from the meta-analysis40.  
Japanese investigators have currently reported that the mortality is significantly 
different between the patients with ‘in-hospital’ versus ‘out-of hospital’ takotsubo 
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syndrome, and in-hospital takotsubo syndrome was associated with the significantly 
higher in-hospital mortality due to the co-existing and triggering malignancy, chronic 
diseases, acute diseases, and infectious diseases16. The mortality in men appears to 
be higher based upon several different sources, albeit with relatively low patient 
numbers in these studies. Gender-related differences, including cardiogenic shock, 
cardiac arrest41 and mortality42, are more apparent for men than women. The 
existence of J wave on ECG in the acute phase is one potential marker of higher risk 
for ventricular tachyarrhythmia and sudden cardiac death45. Although the mechanical 
complications in takotsubo syndrome are not fully understood, they are clinical 
serious and carry a high mortality. Identification of clinical parameters predictive of 
mechanical complications, and understanding of the mechanism(s) underpinning 
them, will aid improvement of clinical treatment pathways.  
Recurrence: The average recurrence rate reported ranges from 0-22% depending 
upon the size of the series and duration of follow up (see table 3). Singh et al. 
reported that the annualized recurrent rate was about 1.5%46 and the cumulative 
incidence of recurrence increased from 1.2% at first 6 months to nearly 5% at 6 
years46. Even in the cases of recurrence, women still dominate this syndrome. In 
young patients aged less than 50 years, the median recurrence rate was perhaps 
surprisingly higher than those aged 50 or more years14. That may reflect a greater 
proportion of younger patients with secondary takotsubo syndrome where the 
triggering event is more likely to recur.  
At the time of writing there is no evidence to support treatment with any specific to 
prevent recurrence. A recent meta-analysis supports this conclusion and reported the 
lack of efficacy of any therapy to prevent reccurence47. Recurrence has been 
reported in the context of β-blockers, which are perhaps the most logical 
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pharmacological preventive strategy, given the stressful trigger and potential role of 
catecholamines. 
  
Pathophysiology 
Based on histological finding 
From many clinical studies the hypothesis of excessive catecholamine as a trigger of 
the takotsubo syndrome has gained more and more attention. The temporal 
relationship between a stressful psychological event and the rapid onset of the 
clinical symptoms, and the number of cases triggered by iatrogenic catecholamine 
administration, support a significant link between catecholamines and the takotsubo 
syndrome. Nonetheless, there was never again such an extensive investigation of 
human biopsies in takotsubo syndrome in the acute phase and after functional 
recovery. Therefore, these descriptive results constitute of an inconceivable value for 
the understanding of this cardiac entity 
 
Insights from clinical histological studies 
Histological studies analyzing myocardial biopsies sampled during the acute phase, 
and at follow up, show that takotsubo syndrome is characterized by mulptiple 
morphological changes that are similar to those after catecholamine cardiotoxic 
effects. An electron microscopic analysis of the myocardium in patients with 
takotsubo syndrome showed a damage of contractile proteins with numerous 
vacuoles of different sizes and contents (myelin bodies, residual cellular products) 
leading to an enlargement of the diameter of the myocytes. Areas of non-specified 
cytoplasm and clusters of mitochondria with abnormalities in size and shape were 
observed. Contraction bands consistent with cytoplasmic calcium overload and fixed 
myofilament crossbridging were sporadically found. Cardiomyocyte nuclei were 
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abnormal in appearance with altered size and location, typically at the border area of 
the cells. Cell swelling associated with damage of the basal lamina, but signs of 
necrosis and oncotic cell death associated with ischaemic injury were not detected. 
Interestingly, the acute catecholamine-induced changes in the composition and 
appearance of the myocardium with disarrangement of the cytoskeletal and 
contractile proteins was restored and reorganized after functional recovery. 
The theory of the direct myocardial toxicity due to catecholamines is further 
supported from the histopathological perspective. Typical structural changes as a 
result of catecholamine overload included a reversible intracellular arrangement (α-
actinin, actin, titin) and a mild neutrophilic infiltration. The presence of myofibroblasts 
in the very early stage of the takotsubo syndrome might play a protective role by 
minimizing the observed myocardial disarray48. 
Significant enlargement of the extracellular matrix (ECM) staining positively for 
collagen-1 was found. This rapid alteration was mainly triggered by an increased ratio 
of collagen α-1 (I) chain to collagen α-1 (III) chain expression and deposition. These 
increased levels of fibrosis were also confirmed by fibronectin staining, and high 
norepinephrine or epinephrine levels might be a potential trigger for the observed 
high levels of profibrotic mediators (angiotensin II and free oxygen radicals). These 
and other factors lead to the activation of transforming growth factor β, stimulating 
connective tissue growth factor and the profibrotic osteopontin49. 
Nevertheless, the degree of fibrosis did not reach critical values therefore structural 
integrity was always maintained. One of the most striking observations in the biopsies 
for patients with takotsubo syndrome is the rapid regression of the abounded fibrosis. 
There is a significant increase of expression and proteolytic activity of matrix 
metalloproteinase-9 (MMP-9) in myocardial biopsies from patients during the acute 
episode of takotsubo syndrome. Proteolytic activity of MMPs, which are regulated by 
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endogenous physiological inhibitors, leads to the degradation of several components 
of the ECM. Therefore, the balance between MMPs, tissue inhibitors of MMPs 
(TIMPs), and their regulators determines the progression of fibrosis in the heart. 
Accordingly, the significant reduction of TIMP-3 mRNA and protein levels during the 
recovery phase of the takotsubo syndrome causes disinhibition of MMP activity, 
which led to increased degradation of the ECM. This could explain the rapid 
regression and reduction in cardiac fibrosis in the takotsubo syndrome49. 
Molecular findings confirmed activation of the PI3K/AKT signaling pathway in 
takotsubo syndrome which might also contribute to a favorable outcome, by 
promoting cell survival and enhancing protein biosynthesis. Both factors are known to 
be essential for myocardial regeneration and improvement of left ventricular 
function50. 
In the acute phase of takotsubo syndrome, immunohistochemical staining for 
marcrophages (CD68) reveald the presence of several extracellular clusters. From 
many reports it is known that leukocyte count and C-reactive protein levels were 
mildly elevated. In the patients with takotsubo cardiomyopathy, injury of the cardiac 
myocytes pre- cedes infiltration of small round cells48. The main pathology of the 
autopsied hearts from the patients with takotsubo syndrome is summarized as 
myocardial injury and its sequelae, which resembled the findings of catecholamine-
induced myocardial injury.  
A number of investigators have additional documented marked elevation of natriuretic 
peptide levels at presentation in such patients. The extent of NT-proBNP/BNP levels, 
correlated with both the peak of catecholamine increase and the severity of LV 
systolic dysfunction. The value of BNP is significantly higher in takotsubo syndrom 
than in acute myocardial infarction. Early BNP/TnT and BNP/CKMB ratios help to 
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differentiate the takotsubo syndrome from acute myocardial infarction with greater 
accuracy than BNP alone51. 
 
Catecholamine-mediated alteration of calcium-regulatory proteins  
The stimulation of β-adrenoceptors (βARs) by supraphysiological levels of 
catecholamines leads to an alteration of the calcium-regulated proteins in takotsubo 
syndrome. The homologous intrinsic membrane proteins Sarcolipin (SLN) and 
Phospholamban (PLN), which are confined to the sarcoplasmic reticulum (SR), are 
critical regulators of cardiac contractility52. An unusually elevated ventricular 
expression of SLN is observed in acute takotsubo syndrome. SLN negatively 
regulates the sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) by 
lowering its affinity for calcium. SLN is located in the same SR membrane 
subcompartments as PLN, inducing a super-inhibitory effect on the SERCA pump. 
PLN, which is also a main regulator of SERCA activity, is also significantly 
upregulated during the acute phase. Perhaps paradoxically in the aftermath of 
intense βAR activation, the PKA-dependent and CamKII-dependent phosphorylation 
pathways are altered leading to a dephosphorylation particularly of the PLN Ser-16 
and the PLN Thr-17, further increasing the inhibitory effect upon SERCA2a53. 
Immunohistochemistry studies showed that the fluorescence intensity of PLN-Ser16 
was lower in biopsies taken from the acute phase compared with healthy 
myocardium. 
Although, there is no direct evidence that the reported alterations in the expression of 
calcium-regulatory proteins are responsible for the acute detrimental effects of 
takotsubo syndrome early results suggest that intense G-protein-stimulated β1-AR 
signaling can directly modulate gene expression via the cyclic AMP-responsive 
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element binding protein 1 and calcineurin-nuclear factor of activated T cells (NFAT) 
signaling pathways54. 
 
Stress hormone-induced disturbance of microcirculation 
An increase of extracellular fibrosis is usually associated with disturbed 
microcirculation. In takotsubo syndrome a significant reduction in capillary density 
was documented. Endomyocardial capillaries were visualized by 
immunohistochemical staining for CD3148, 49. This was mainly due to the expansion 
of the ECM, which then led to a relative decrease in the supplying capillaries. This 
ultimately results in a mismatch between oxygen supply and demand in 
cardiomyocytes. In a recent study, ultrastructural analyses of myocardial tissue 
clearly showed intracellular vacuoles and intracellular accumulation of ubiquitin in the 
acute takotsubo syndrome48. These results indicate a potential oxygen deficiency 
contributing to cardiomyocyte dysfunction. 
  
The central role of catecholamines 
The pathophysiology of takotsubo syndrome is complex and reflects the integrated 
cardiovascular responses to sudden surges in endogenous, or exogenously 
administered, catecholamines, often in the context of acute severe stress. There are 
also several clinical conditions, including acute subarachnoid haemorrhage, 
phaeochromocytoma and acute thyrotoxicosis, which are associated with acute 
severe sympathetic neural activation or adrenal catecholamine release which can 
trigger takotsubo syndrome. Many observational clinical studies, and a few laboratory 
models, have helped to provide the current basis for several pathophysiological 
hypotheses. The role of catecholamines appears central to the pathophysiology of 
takotsubo syndrome, and catecholamines have multiple direct and indirect effects on 
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the brain, systemic vasculature, coronary vasculature and myocardium which may be 
relevant.  
The pathophysiology can be broadly considered in two phases. The first starts with 
the cognitive centres of the brain and hypothalamic-pituitary-adrenal (HPA) axis, and 
how much epinephrine and norepinephrine are released in response to a given 
stress i.e. the ‘gain’ of the hypothalamic-pituitary-adrenal axis. Serum catecholamine 
levels in patients with takotsubo syndrome at presentation are significantly elevated 
compared both to resting levels in the same patient and to levels in comparable 
patients with acute heart failure secondary to acute myocardial infarction, suggesting 
the potential for excessive HPA gain and epinephrine release in susceptible 
individuals55. This is most relevant for takotsubo syndrome cases triggered by 
emotional stress. The thresholds for stress tolerance, and HPA gain, are incompletely 
understood, but there is supporting evidence that this may be important in some 
cases. The incidence of stress and anxiety disorder is higher in cohorts of Takotsubo 
syndrome patients compared to control emergency populations10. This may reflect a 
risk or predisposition rather than the sole causative issue. It is well established that 
there are higher resting levels of catecholamines in individuals with panic disorder, 
contributing to their clinical syndrome, and it is plausible that these individuals are 
predisposed to a higher norepinephrine and epinephrine surge for a given stress 56. A 
recent study of the circulating microRNA profile of takotsubo syndrome patients 
showed striking difference compared to the control group of STEMI57. In particular, 
there was the higher levels of miR16 and miR26a which has been associated with 
neuropsychiatric disease. In summary in some individuals with takotsubo syndrome 
there may be pre-existing anxiety disorder phenotype, and identification may lead to 
appropriate treatment strategies in order to aid management strategies for future 
stressful episodes. 
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The second is the cardiovascular response to the sudden sympathetic activation and 
surge in circulating catecholamines. A number of hypotheses have been proposed to 
explain takotsubo syndrome and the cardiac response to severe stress. The three 
predominant hypotheses are reviewed below, and whilst these have been proposed 
in isolation, it is becoming increasingly apparent that they may not be mutually 
exclusive given the entire cardiovascular system is exposed to the same 
‘catecholamine storm’. The potential for combinations of multivessel vasospasm, 
increased ventricular afterload from the surge of systemic vasoconstriction and 
arterial hypertension, and the impact of the high catecholamines directly upto the 
myocardium dictated by βAR gradients may contribute to yield a final common 
endpoint of acute apical dysfunction (see Figure 2). Taking an integrated approach 
may be a path to understand the diverse range of experimental and clinical 
observations reported. For example, it is plausible that multivessel vasospasm and 
catecholaminergic myocardial stunning may co-exist, with the latter modifying the 
myocardial response to ischaemic via activation of cardioprotective signalling 
pathways. These are evident in the preclinical models and in the biopsy specimens 
from patients during the acute phase (see above). Concomitant vasospasm, driven 
by high norepinephrine and epinephrine levels via α-adrenoceptors in the vasculature, 
and myocardial stunning via βAR signalling, is highly likely given the systemic 
activation and surges in catecholamines. The impact of peripheral vascular 
responses with vasoconstriction, systemic arterial hypertension and elevated 
afterload, versus vasodilatation, hypotension and reduced afterload, may also be 
relevant in determining both the anatomical variant (see below), and the susceptibility 
to various complications such as acute left ventricular outflow tract obstruction, which 
may further exacerbate the developing acute failure syndrome. 
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Acute multivessel coronary spasm 
Many of the initial Japanese takotsubo syndrome cases described had multivessel 
vasospasm at diagnostic coronary angiography, and it is conceivable that a number 
of individuals may be prone to stress-induced multivessel coronary artery spasm. In 
subsequent series the incidence of vasospasm has been variable, but spontaneous 
vasospasm is observed in ~5-10% cases. Vasospastic provocation has been studied 
during the acute phase, with evidence in 10-43% patients in various series58,59. In 
non-Japanese populations, especially when performed in the convalescent phase or 
later, epicardial coronary vasospasm is not a common finding, whereas 
microvascular dysfunction was more common60. A review of 9 cohort studies 
concluded provocation-induced vasospasm was present in 34 of 123 patients studied 
(27.6%)61. One group report that the inducible vasospasm with acetylcholine 
provocation at follow up lead to recapitulation of the acute apical dysfunction, 
supportive of the potential role of multivessel vasospasm, at least in some cases of 
the apical variant62. Further studies suggest endothelin levels may be higher in 
patients with acute takotsubo syndrome57. Endothelin is an extremely potent 
vasoconstrictor, and could be a potential mechanism to trigger multivessel 
vasospasm. In addition after any stress and high surge in catecholamines, 
generalised impairment of endothelial function secondary to oxidative stress is to be 
expected, and both coronary and peripheral arteries may be prone to vasospasm 
upon provocation. The distinction between cause and association is important to 
distinguish before all cases of Takotsubo syndrome can be explained by multivessel 
vasospasm. However whilst in some cases vasospasm correlates with the region of 
dysfunction, equally in other cases it did not, leading some authors to conclude that 
vasospasm plays no role in the aetiology of takotsubo syndrome63. Anatomical 
abnormalities regarding coronary arteries have also been observed in patients with 
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takotsubo syndrome, i.e. myocardial bridging64 and hypoplastis coronary arteries65, 
but there is no evidence to suppot a causative role. 
A number of clinical cases reported were triggered by either dobutamine66, a 
vasodilator with minimal vasospastic effects, or epinephrine, which also has a 
dominant coronary vasodilatory effect, and therefore would not support vasospasm 
as the primary mediator. Likewise in preclinical models high doses of the βAR 
agonist isoproterenol can trigger acute apical dysfunction, supporting the hypothesis 
that vasospasm is not essential for an acute takotsubo phenotype. These studies 
have also shown normal myocardial perfusion when studied using bubble-contrast 
echocardiography during the development of apical dysfunction following 
isoproterenol injection67. There are also significant differences in histopathological 
features with endomyocardial biopsies taken from patients with takotsubo syndrome 
showing a pattern of myocardial abnormalities not associated with infarcted, stunned, 
or hibernating myocardium, which would not support a primary vascular cause (see 
above)48. 
 
Direct catecholamine-mediated myocardial stunning 
A number of different groups have suggested that the surge of high circulating 
catecholamine levels may have a direct effect upon the ventricular myocardium which 
can cause the apical ballooning pattern observed. Several years ago one of the 
authors (ARL) proposed a hypothesis in this journal which could explain the 
anatomical pattern of myocardial dysfunction in acute takotsubo syndrome 68. The 
β2AR hypothesis reflects the repeated observation of apical-basal gradients of 
sympathetic nerve endings and βARs in mammalian hearts68. A consistent finding 
across several mammalian species, including humans, is a higher sympathetic nerve 
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density in the basal myocardium compared to the apex69. Therefore the location of 
cardiac sympathetic nerve terminals does not explain apical hypokinesia, the most 
common anatomical variant, although they may have a role in the basal or inverted 
takotsubo variant. In contrast, the apical myocardium of the left ventricle has the 
highest density of βARs in several studies of non-human mammalian hearts, and is 
therefore most sensitive to circulating catecholamines including exogenous 
catecholamine administration70-72, although this remains to be clarified in human 
hearts. These opposing apical-basal sympathetic nerve and βAR gradients allow 
balanced myocardial responses to sympathetic activation under normal levels of 
sympathetic activation, for example during exercise or mild stresses. However at the 
highest levels of circulating epinephrine, released systemically from the adrenal 
glands in the context of extreme stress, the βAR receptor gradient would determine 
the dominant response within the ventricular myocardium.  
Whereas epinephrine is generally viewed as a positive inotrope, this is only the case 
at low and medium concentrations. Several studies demonstrate that it has a bell-
shaped dose-response relationship for myocardial contraction, and at the highest 
doses epinephrine is a negative inotrope via the β2AR73,74. This is a pharmacological 
property of the βAR known as stimulus trafficking, where high epinephrine levels 
result in a switch from the Gs stimulatory to the cardioinhibitory Gi secondary 
messenger pathway within the cardiomyocyte68,73. β2AR-Gi pathway activation is 
cardioprotective via activation of a number of antiapoptotic pathways75 and this may 
minimise the toxic effects of vasospastic ischaemia, pressure-induced injury from 
high intracavity pressures, and the excessive catecholaminergic stimulation upon the 
myocardium. It is important to note that whilst β2AR-Gi signalling has been 
demonstrated in human hearts with chronic heart failure, it has yet to be confirmed in 
human hearts during acute takotsubo syndrome. Activation of these patways is noted 
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in the moyocardial biospies from takotsubo syndrome patients during the acute 
phase as noted above. This hypothesis was tested in a rat takotsubo model where 
high dose epinephrine-induced reversible apical hypokinesia, and this takotsubo 
model could be prevented by pretreatment with the Gi protein inhibitor pertussis 
toxin72. This observation was replicated in another preclinical model where pertussis 
toxin prevented acute apical dysfunction induced by high dose isoproterenol injection, 
albeit with a high mortality in the pertussis toxin treated group76. Recently computer 
modelling studies evaluated the impact of varying βAR gradients across the left 
ventricle under different haemodynamic situations and could replicate the acute 
apical dysfunction observed when the βAR density was highest at the apex77.  
 
Excessive transient ventricular afterload and takotsubo variants 
The peripheral circulatory and systemic responses to an acute catecholamine 
administration are dramatic, whether observed clinically or in the research laboratory. 
In the rat epinephrine model, within seconds of intravenous epinephrine injection 
there is severe peripheral vasoconstriction causing a surge or both systolic and 
diastolic hypertension72. Peak systolic pressure was initially >250mmHg, with 
diastolic pressure >100mmHg, activating the vagal reflex and sinus bradycardia72. 
This severe acute arterial hypertension lasts only a few minutes, and during this 
hyperacute phase the heart has a hypercontractile state. This finding has been 
recently confirmed in a case report where the authors found that during the 
hyperacute phase of takotsubo syndrome there was a hypertensive crisis associated 
mainly with basal hyperkinesis78, and hypertensive crises are frequently observed in 
patients with subarachnoid haemorrhage and phaeochromocytoma. The 
physiological state evolves into a secondary phase with developing acute apical 
dysfunction, normotension or hypotension, frequently complicated by cardiogenic 
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shock, and either persisting vasoconstriction or paradoxical vasodilation given the 
impaired cardiac function.  
Considering these temporal phases is important when interpreting the clinical and 
preclinical observations and the role of haemodynamics and ventricular-arterial 
coupling, and has recently been reviewed79. The wall stress imparted by the high 
intracavity pressures may initiate regional dysfunction. The potential for the 
hypertensive storm to cause acute myocardial dysfunction has been explored using a 
variety of catecholamines with some intriguing findings80. Administration of primary 
vasoconstrictors, causing high afterload, frequently triggered the inverted or basal 
takotsubo variant. One might expect them to trigger coronary vasospasm and apical 
dysfunction, but this was not the case in this reported study. In contrast 
catecholamines which reduce peripheral vascular resistance via vasodilation, with 
lower systolic blood pressure and ventricular afterload, were more likely to cause the 
typical apical variant78. This is interesting as some patients have systemic arterial 
vasodilatation and low systemic vascular resistance, which may reflect maladaptive 
regulation by the peripheral sympathetic nervous system33,81. This is usually 
measured hours after the initial stressful trigger and catecholamine surge, and so 
whether it is present immediately during the acute stress remains to be clarified. It is 
clear that there are abnormalities of peripheral sympathetic nerve function and 
arterial vasomotor regulation in the aftermath of the acute catecholamine storm33, 80-
82. These vasodilating catecholamines may also activate myocardial β2ARs in 
addition to vascular β2ARs, and therefore this may reflect a mixed effect. 
It is conceivable that the multiple factors altering myocardial physiology, including the 
acutely elevated, afterload insult and ischaemia from coronary vasospasm in the 
immediate seconds and minutes after the surge in endogenous catecholamines, 
followed by the subsequent reduction in contractile responses due of β2-Gi signalling 
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and activation of cardioprotective pathways, may occur in concert resulting in the 
clinical pattern of apical dysfunction observed. Some individuals may be more 
susceptible to one pathophysiological mechanism which could dominate. For 
example one study reported that individuals with takotsubo syndrome carried the 
GRK5L41Q polymorphism which is a gain-of-function polymorphism for the GRK5 
enzyme83. The GRK5 kinase phosphorylates β2AR and activates stimulus trafficking. 
Therefore individuals harbouring this polymorphism may developed negative 
inotropic responses to epinephrine at lower levels, and may also have greater 
vasodilatory responses84. The two in combination would potentially lower the 
threshold for inducing apical dysfunction in the context of acute stress. However 
other genetic studies have failed to replicate this finding85, and therefore this may 
reflect a susceptibility genetic effect rather than absolute cause.  
 
Post-menopausal hormonal status and catecholaminergic responses 
Given the central role of catecholamines and the strong predisposition for occurrence 
in postmenopausal women, the potential role of chronic oestrogen exposure, and 
loss of the sympatholytic effects of oestrogens, should be considered. It is well 
established that oestrogens reduced the inotropic and chronotropic responses to 
catecholamines, alter vascular reactivity and are cardioprotective86-88. Several studies 
demonstrate that myocardial βAR-mediated positive inotropic responses are greater 
in male hearts than matched female hearts, and these differences are mediated by a 
lower level of β1AR-signalling. The reduced myocardial β1AR-signalling in ovulating 
females appears protective from myocardial insults including high catecholamines 
from stress stimuli as well as ischaemia-reperfusion injury29, 89. Oophrectomy 
removes this protective effect in preclinical models, and is associated with an 
increase in β1AR-signalling and inotropy. In a specific model of stress-induced 
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takotsubo syndrome by conscious restraint, oestrogen supplementation to 
oophrectomised animals reduced the apical dysfunction observed during stress30,86. 
Oestrogens also increase vascular β2AR-mediated vasoreactivity, and their loss 
following menopause could lead to greater vasoconstriction with reduced β2AR-
mediated vasodilatation in the setting of high stress-induced surges in 
catecholamines. 
More research is required to help clarify the particular role of each of the hypotheses 
discussed, in order to further understand the cardiovascular responses to acute 
stress, and the pathophysiology underpinning takotsubo syndrome.  
 
Conclusion 
Takotsubo syndrome is an acute cardiac syndrome first described in 1990 and 
characterized by transient left ventricular dysfunction affecting more than one 
coronary artery territory, and often in a circumferential apical, mid-ventricular or basal 
distribution. Currently there is a growing awareness that these are not mutually 
exclusive and that the reversible apical myocardial dysfunction observed could result 
from more than one pathophysiological phenomenon. It is clear that the modern 
cardiology community has much still to learn regarding the epidemiology and the 
underlying pathophysiology of this fascinating condition in order to improve 
diagnostic and treatment pathways.  
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Figure legends 
Fig.1:(A) Immunohistochemistry of intracellular proteins. a-actinin (specific labelling 
green, phalloidin red, nuclei blue) was detected only in the border zone of patients 
with takotsubo syndrome48. (B) The extracellular matrix  stained with collagen‐1 
(green) was increased and the myocardial syncytium was separated48. (C) 
Myofibroblasts are detected in takotsubo syndrome confirming the hypothesis of a 
catecholamine triggered depression of left ventricle. (D) The capillary density stained 
by CD31 (green) was reduced in patients with Takotsubo syndrome49. (E) Most 
notable, Sarcolipin (red) was present in the left ventricle during the acute phase of 
takotsubo syndrome contributing to a disturbed regulation of calcium homeostasis90. 
(F) Electron microscopy of biopsies from patients with takotsubo syndrome showing 
numerous vacuoles of different sizes and contents (myelin bodies, residual cellular 
products), loss of contractile material, and areas of non-specified cytoplasm. The 
interstitial space was widened containing formation of cellular debris  and 
contraction bands (*) of sarcomeres were found48. All figures were adapted and 
modified with permission.  
 
Fig 2: Integrated pathophysiological model for acute takotsubo syndrome. (A) Normal 
left ventricular systolic performance under normal conditions of perfusion, afterload 
and βAR activation. (B) Acute Takotsubo syndrome triggered by a mixed combination 
of multivessel vasospasm, transient increased afterload from high aortic and left 
ventricular endsystolic pressure, followed by subsequent reduction with systemic 
hypotension, and excessive activation of myocardial βARs with an apical 
predominance reflecting their high expression. 
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Table 1. Diagnostic criteria from the previous report 
  
 
 Mayo Clinic 
Criteria, 
the U.S. 6 
Gothenburg 
Criteria, 
Sweden 7 
MRI-based Criteria, 
Europe and the U.S. 8 
Italian Network 
Criteria, 
Italy 9 
1. Transient 
akinesis or 
dyskinesis of 
left ventricular 
wall motion 
abnormalities 
(ballooning) 
with chest pain 
1. Transient 
hypokinesis, 
akinesis, or 
dyskinesis in the 
left ventricular 
segments and 
frequently, but not 
always, a stressful 
trigger (psychical 
or physical). 
1. An acute cardiac 
event typically 
presenting with chest 
pain and/or dyspnea 
1. Typical transient 
LV wall motion 
abnormalities 
extending beyond 
a single epicardial 
vascular 
distribution with 
complete functional 
normalization 
within 6 weeks 
2. New 
electrocardiogr
aphic changes 
(either ST-
elevation or T-
wave 
inversion) 
2. The absence of 
other pathological 
conditions 
(e.g. ischemia, 
myocarditis, toxic 
damage, 
tachycardia, etc.) 
that may more 
credibly explain the 
regional 
dysfunction. 
2. Transient systolic 
dysfunction with 
marked LV contraction 
abnormality (akinesia 
or dyskinesia of the LV 
apical and/or 
midventricular or basal 
segments) 
2. Absence of 
potentially culprit 
coronary stenosis, 
or angiographic 
evidence of acute 
plaque rupture, 
dissection,thrombo
sis or spasm 
3. No 
significant 
obstructive 
epicardial 
coronary artery 
disease 
3. No elevation or 
modest elevation in 
cardiac troponin 
(i.e. disparity 
between the 
troponin level and 
the amount of the 
dysfunctional 
myocardium 
present).  
3. Absence of 
significant (>50%) 
obstructive coronary 
artery disease or 
angiographic evidence 
of acute plaque rupture 
3. New and 
dynamic ST-
segment 
abnormalities or T-
wave inversion as 
well as new onset 
of transient or 
permanent left 
bundle branch 
block 
4. Absence of 
pheochromocyt
oma or 
myocarditis 
 
4. New 
electrocardiographic 
abnormalities (either 
ST elevation or T-wave 
inversion) or modest 
elevation in cardiac 
troponin level 
4. Mild increase in 
myocardial injury 
markers (creatine 
kinase-MB value < 
50 U/L) 
  
5. Absence of 
pheochromocytoma 
5. Clinical and/or 
instrumental 
exclusion of 
myocarditis 
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6. Absence of 
myocarditis or typical 
ischemic transmural 
late gadolinium 
enhancement on 
cardiovascular 
magnetic resonance (if 
available). 
6. Post-
menopausal 
woman (optional) 
  
 7. Antecedent 
stressful event 
(optional) 
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Table 2. Various stressors (modified from Reference 91 92 with permission)  
Emotional stress 
 Anger 
 Accident 
 Death or severe illness or injury of a family member, friend, or pet 
 Earthquake 
 Financial loss - business, gambling 
 Involvement with legal proceedings 
 Move to a new residence 
 Panic 
 Public speaking 
 Receiving bad news - diagnosis of a major illness, one’s divorce, 
spouse leaving for war 
 Severe argument 
 Surprise party 
Physical stress 
 Anemia due to gastrointestinal bleeding 
 Cocaine use  
 Drug reaction 
 Electroconvulsive theraphy 
 Excessive insulin administration 
 Noncardiac surgery or procedure - cholecystectomy, hysterectomy, 
nosebleed treated with phenylephrine  
 Recovery from general anesthesia 
 Severe illness - asthma or acute exacerbation of chronic obstructive 
airway disease, connective tissue disorders, acute cholecystitis, 
encephalitis, fracture, subarachnoid hemorrhage, 
pseudomembranous colitis, cancer, endocrine neoplasia, 
thyrotoxicosis 
 Severe pain - fracture, renal colic, pneumothorax, pulmonary 
embolism 
 Stress test - dobutamine stress echocardiogram, exercise 
 Suicide attempt 
 Withdrawal from alcohol, opiate 
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Table 3. Recurrence rate from the previous reports (modified from Reference 46 with 
permission) 
 
  
Authors Country 
Reported 
year 
Recurrence 
cases/ all 
subjects 
Recurrence 
rate (%) 
Tsuchihashi, et al. 
59
 Japan 2001 2/72 2.8 
Desmet, et al. 
93
 Belgium 2003 1/13 7.7 
Bybee, et al. 
94
 U.S.A 2004 1/16 6.2 
Akashi, et al. 
95
 Japan 2005 0/13 0 
Sharkey, et al. 
96
 U.S.A 2005 1/11 9.1 
Gianni, et al. 
97
 Italy, Canada 2006 6/169 3.5 
Hertting, et al. 
98
 Germany 2006 0/32 0 
Kurowski, et al. 
11
 Germany 2007 2/35 5.7 
Elesber, et al. 
31
 U.S.A 2007 10/100 11.4 
Spedicato, et al. 
99
 Italy 2008 2/29 6.9 
El Mahmound, et al. 
100
 France 2008 0/32 0 
Previtali, et al. 
101
 Italy 2009 1/18 5.6 
Eshtehardi, et al. 
102
 Switzerland 2009 2/41 4.9 
Regnante, et al. 
103
 U.S.A 2009 2/70 2.9 
Teh, et al. 
104
 Australia 2010 0/23 0 
Primetshofer, et al. 
13
 Austria 2010 1/31 3.2 
Sharkey, et al. 
32
 U.S.A 2010 7/136 5.1 
Song, et al. 
34
 Korea 2010 0/87 0 
Parodi, et al. 
105
 Italy 2011 2/116 1.7 
Nunez-Gil, et al. 
106
 Spain 2012 4/100 4.0 
Brenner, et al. 
107
 Switzerland 2012 2/17 11.7 
Samardhi, et al. 
108
 Australia 2012 0/51 0 
Bellandi, et al. 
109
 Italy 2012 0/105 0 
Cacciotti, et al. 
110
 Italy 2012 1/75 1.3 
Vriz, et al. 
42
 Italy 2013 5/23 21.7 
Sharma, et al. 
111
 U.K. 2013 0/12 0 
Pullara, et al. 
112
 Italy 2013 2/26 7.7 
Patel, et al. 
14
 U.S.A 2013 7/224 3.1 
Showkathali, et al. 
113
 U.K. 2014 0/17 0 
Murakami, et al. 
15
 Japan 2014 9/107 4.7 
Nishida, et al. 
28
 Japan 2014 7/251 2.8 
Sum and average   77/2052 3.8 
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